Marijuana and Cardiovascular Health: What Research Shows About Heart Risks

Executive Summary

Emerging research links marijuana use to increased cardiovascular risks, including heart attacks, strokes, and arrhythmias, even as legalization expands nationwide. A May 2026 study published in the Journal of the American Heart Association found that daily cannabis users faced a 25% higher risk of heart attack and 42% higher risk of stroke compared to non-users, independent of tobacco use. These findings arrive as 38 states have legalized medical marijuana and 24 have approved adult-use programs, creating urgent questions for the estimated 55 million Americans who use cannabis regularly. The cardiovascular concerns center on THC's effects on heart rate, blood pressure, and vascular inflammation. When inhaled, delta-9-tetrahydrocannabinol (THC) triggers immediate increases in heart rate—sometimes by 20-50 beats per minute—and can cause blood pressure fluctuations that stress arterial walls. Cardiologists now document cases of cannabis-induced myocardial infarction in patients as young as their twenties, a demographic traditionally at low cardiac risk. This topic matters to patients managing chronic conditions, physicians navigating treatment protocols, dispensary operators counseling customers, insurers assessing risk pools, and policymakers balancing public health against individual liberty. As the FDA considers rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act, understanding cardiovascular impacts becomes essential for evidence-based regulation. The intersection of expanding access and emerging health data creates both clinical challenges and opportunities for harm reduction through patient education and product innovation.

Why This Matters

The cardiovascular health debate affects 161 million American adults with hypertension, 18 million with coronary artery disease, and millions more using cannabis therapeutically. The scale is staggering. According to the National Survey on Drug Use and Health, 49 million Americans used marijuana in 2025, with 17 million reporting daily or near-daily use. Among medical marijuana patients, cardiovascular disease ranks as a common comorbidity: approximately 35% of patients over age 50 enrolled in state programs have documented heart conditions or risk factors including diabetes, obesity, or hyperlipidemia. Financial stakes run into billions. The U.S. cannabis market generated $33.6 billion in sales in 2025, with medical sales comprising $8.2 billion. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries serve millions of patients who may face cardiovascular risks. If labeling requirements or physician warnings reduce consumption among at-risk populations, revenue impacts could reach hundreds of millions annually. Healthcare costs compound the concern. Cardiovascular disease already costs the U.S. economy $407 billion annually in direct medical expenses and lost productivity, according to the American Heart Association. If cannabis use contributes even marginally to heart attack and stroke incidence, the incremental cost could exceed $2 billion per year when accounting for emergency department visits, hospitalizations, rehabilitation, and disability. Physicians face clinical dilemmas daily. Cardiologists report patients using cannabis to manage chronic pain, anxiety, or insomnia—conditions that pharmaceutical alternatives may address less effectively or with worse side effect profiles. The absence of randomized controlled trials leaves doctors weighing observational data against patient preferences, often without clear guidance from professional societies. Vulnerable populations bear disproportionate risk. African American adults experience cardiovascular disease at higher rates and also face higher cannabis arrest rates despite similar usage patterns to white Americans. As legalization progresses, ensuring equitable access to health information becomes a justice issue alongside a medical one.

Background and History

The connection between marijuana and heart health has evolved from anecdotal case reports in the 1970s to large-scale epidemiological studies revealing measurable cardiovascular risks.

Early Case Reports (1970s-1990s)

The first documented cases of cannabis-associated myocardial infarction appeared in medical literature in 1979, when researchers at the University of California, San Francisco published a case series in the New England Journal of Medicine describing three young men who suffered heart attacks shortly after smoking marijuana. All three patients lacked traditional cardiac risk factors such as hypertension, diabetes, or family history, leading investigators to suspect cannabis as the precipitating cause. Throughout the 1980s, emergency department physicians reported sporadic cases of chest pain, arrhythmias, and acute coronary syndrome in cannabis users. These reports remained largely anecdotal, dismissed by many as coincidental or confounded by concurrent tobacco use. The Reagan administration's "Just Say No" campaign politicized drug research, making objective cardiovascular studies difficult to fund or conduct.

Mechanistic Research Emerges (1990s-2000s)

The 1990s brought breakthroughs in understanding the endocannabinoid system. In 1992, Raphael Mechoulam and colleagues at Hebrew University identified anandamide, the first endogenous cannabinoid, followed by the discovery of CB1 and CB2 receptors throughout the body. Researchers found CB1 receptors densely concentrated in the cardiovascular system, including the heart, blood vessels, and autonomic nervous system. Laboratory studies demonstrated that THC binding to CB1 receptors triggers sympathetic nervous system activation, increasing heart rate and myocardial oxygen demand. A landmark 2001 study in Circulation showed that marijuana smoking increased heart rate by an average of 29 beats per minute within 10 minutes, with effects lasting up to three hours. For patients with existing coronary artery disease, this increased cardiac workload could precipitate ischemia. Research also revealed that cannabis smoke contains many of the same inflammatory compounds as tobacco smoke, including carbon monoxide, tar, and oxidative chemicals that damage endothelial cells lining blood vessels. A 2005 study published in the European Heart Journal found that marijuana smoking impaired flow-mediated dilation—a measure of vascular health—to a degree comparable to tobacco.

Population Studies Identify Risks (2008-2015)

As state medical marijuana programs expanded following California's 1996 Proposition 215, researchers gained access to larger patient populations. A 2008 study analyzing data from the National Health and Nutrition Examination Survey found that marijuana users had higher rates of hypertension and metabolic syndrome compared to non-users, even after adjusting for tobacco use, alcohol consumption, and body mass index. The 2014 French Addictovigilance Network study examined 1,979 cannabis-related health complications reported between 2006 and 2010. Cardiovascular events accounted for 25.6% of cases, including 122 acute coronary syndromes and 76 cases of peripheral arterial disease. The median age of cardiovascular patients was just 34 years, and nine deaths occurred—a mortality rate that alarmed public health officials. A 2015 study in the Journal of the American Heart Association tracked 3,617 heart attack survivors and found that marijuana use in the year prior to the event increased the risk of death in the following 18 years by 29%. The mechanism appeared related to recurrent ischemic events and arrhythmias in patients with damaged myocardium.

Legalization Era and Expanded Research (2016-2024)

Adult-use legalization in Colorado (2014) and Washington (2014) created natural experiments for cardiovascular research. A 2019 Stanford University study analyzed emergency department visits in Colorado and found a 29% increase in cannabis-related cardiovascular events in the three years following legalization, with acute coronary syndrome cases rising from 2.4 to 3.1 per 10,000 visits. The 2020 American Heart Association scientific statement on marijuana and cardiovascular health synthesized decades of research, concluding that cannabis use "may be associated with increased risk of cardiovascular events" and recommending that patients with cardiovascular disease avoid marijuana. The statement cited evidence for increased heart attack risk in the hour following use, stroke risk with chronic use, and peripheral arterial disease in young users. During the COVID-19 pandemic, researchers identified cannabis use as a potential risk factor for severe outcomes. A 2021 study in the Journal of Adolescent Health found that young adults who used cannabis had higher rates of COVID-19 hospitalization, possibly due to compromised pulmonary and cardiovascular function.

Current Research Landscape (2025-2026)

The May 2026 study that triggered renewed attention analyzed data from 175,000 participants in the National Health Interview Survey between 2016 and 2022. Researchers at Massachusetts General Hospital found that daily marijuana users had a 25% higher risk of heart attack and 42% higher risk of stroke compared to non-users, with risks increasing proportionally to frequency of use. Notably, the association held even among participants who had never smoked tobacco, addressing a major confounding variable in earlier studies. Concurrent research has focused on alternative consumption methods. A 2025 study in JAMA Cardiology found that vaping THC concentrates produced similar cardiovascular effects to smoking flower, with heart rate increases of 22-35 beats per minute. Edible cannabis products showed more variable effects, with delayed onset but prolonged duration of cardiovascular stress. The National Institutes of Health launched a $15 million longitudinal study in 2024 to track cardiovascular outcomes in 10,000 medical marijuana patients across six states, with results expected in 2029. This represents the largest prospective cardiovascular study of cannabis users to date.

Key Players

American Heart Association

The American Heart Association has emerged as the leading medical voice on cannabis cardiovascular risks. The organization's 2020 scientific statement marked a turning point, providing cardiologists with evidence-based guidance after years of uncertainty. The AHA recommends that patients with known cardiovascular disease avoid marijuana and that healthcare providers screen for cannabis use when assessing cardiac risk factors. The association has called for FDA regulation of cannabis products similar to tobacco, including warning labels about cardiovascular risks.

National Institute on Drug Abuse

NIDA funds the majority of federal cannabis research, including cardiovascular studies. The agency operates the Drug Supply Program at the University of Mississippi, which provides standardized cannabis to researchers—though critics note the material's lower potency compared to commercial products. NIDA Director Nora Volkow has testified before Congress about cardiovascular risks, particularly among adolescents and young adults whose use patterns have shifted toward high-potency concentrates.

Food and Drug Administration

The FDA's ongoing review of marijuana rescheduling under 21 U.S.C. § 812 includes cardiovascular safety as a key consideration. If cannabis moves from Schedule I to Schedule III, the agency would gain regulatory authority over medical products, potentially requiring cardiovascular warnings similar to those mandated for tobacco under the Family Smoking Prevention and Tobacco Control Act. The FDA's Center for Drug Evaluation and Research is reviewing pharmacokinetic data on THC's cardiac effects.

Multi-State Operators

Major cannabis companies face pressure to address health concerns while maintaining market share. Curaleaf, the largest MSO by revenue, launched a cardiovascular health education initiative in 2025, training dispensary staff to screen patients for cardiac risk factors. Trulieve includes cardiovascular warnings in patient education materials distributed at its 186 locations. Green Thumb Industries partnered with the American College of Cardiology to develop patient screening tools. These efforts aim to demonstrate corporate responsibility while preempting mandatory regulations.

American College of Cardiology

The ACC has published clinical guidance for cardiologists treating patients who use cannabis. The organization's 2024 expert consensus document recommends obtaining detailed cannabis use histories, including consumption method, frequency, and potency. The ACC advises particular caution in patients with coronary artery disease, heart failure, or arrhythmias, and recommends against cannabis use in the perioperative period due to increased cardiac event risk.

NORML

The National Organization for the Reform of Marijuana Laws has challenged what it characterizes as "alarmist" cardiovascular research, arguing that observational studies cannot establish causation and that risks remain small compared to alcohol and tobacco. NORML Deputy Director Paul Armentano has testified that cardiovascular concerns should not impede legalization but rather inform patient education and harm reduction strategies. The organization advocates for research into CBD-dominant products that may lack THC's cardiovascular effects.

Legal and Regulatory Framework

Federal law classifies marijuana as a Schedule I controlled substance under 21 U.S.C. § 812, creating legal barriers to cardiovascular research and physician guidance. The Controlled Substances Act of 1970 placed cannabis in Schedule I, defined as substances with "no currently accepted medical use" and "high potential for abuse." This classification requires researchers to obtain DEA registration, navigate FDA investigational new drug applications, and source material from the single federally licensed cultivator at the University of Mississippi—a process that can take years and limit study designs. The 2018 Farm Bill (Agricultural Improvement Act, Pub. L. 115-334) legalized hemp containing less than 0.3% THC, creating a legal market for CBD products. However, the FDA has not approved CBD for cardiovascular indications, and the agency has issued warning letters to companies making unsubstantiated heart health claims. The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331) prohibits marketing unapproved drugs, giving the FDA authority to regulate cardiovascular claims. The Rohrabacher-Farr Amendment (now Rohrabacher-Blumenauer), renewed annually in appropriations bills, prohibits the Department of Justice from using funds to interfere with state medical marijuana programs. This has allowed state-legal research to proceed, though federal funding remains restricted. In August 2023, the Department of Health and Human Services recommended rescheduling marijuana to Schedule III, citing accepted medical use. The DEA's administrative law judge process, required under 21 C.F.R. § 1308, is ongoing as of May 2026. Schedule III status would maintain criminal penalties for unauthorized use but acknowledge medical applications and potentially ease research restrictions. State medical marijuana laws typically require physician certification rather than prescription, sidestepping the federal prohibition on prescribing Schedule I substances. However, few states mandate cardiovascular screening or warnings. California's Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) requires general health warnings but not specific cardiovascular language. Massachusetts regulations require dispensaries to provide educational materials on health risks, including cardiovascular effects, under 935 CMR 500.105. Professional liability creates additional legal considerations. Physicians who recommend cannabis to patients with cardiovascular disease face potential malpractice claims if adverse events occur. The standard of care remains evolving, with courts likely to examine whether physicians obtained adequate medical history, discussed risks, and documented informed consent. No appellate court has yet ruled on cannabis-related cardiovascular malpractice, leaving liability uncertain.

State-by-State Breakdown

State medical marijuana programs vary widely in their approach to cardiovascular risk disclosure and patient screening.

California

California's program, established by Proposition 215 in 1996 and expanded under MAUCRSA, serves approximately 750,000 registered medical patients. The state requires dispensaries to provide written materials on health risks but does not mandate cardiovascular-specific warnings. The California Department of Public Health issued guidance in 2024 recommending that physicians discuss cardiovascular risks with patients over 50 or those with known heart disease. Possession limits allow up to eight ounces of flower for medical patients.

Colorado

Colorado legalized medical marijuana in 2000 and adult use in 2012 under Amendment 64. The state's Medical Marijuana Code (12 CCR 2850-10) requires dispensaries to provide educational materials but does not specify cardiovascular content. The Colorado Department of Public Health and Environment published a 2025 fact sheet on cannabis and heart health following the Stanford emergency department study. Medical patients may possess up to two ounces; the program enrolled 78,000 patients as of 2025.

Florida

Florida's medical program, authorized by Amendment 2 in 2016 and implemented under Florida Statutes § 381.986, serves over 800,000 patients—the nation's largest per-capita enrollment. The state requires physicians to complete a four-hour education course that includes cardiovascular risk discussion. The Florida Board of Medicine issued guidance in 2023 recommending cardiovascular assessment for patients over 55. Patients may purchase up to 2.5 ounces of flower every 35 days.

Illinois

Illinois legalized medical use in 2013 and adult use in 2020 under the Cannabis Regulation and Tax Act (410 ILCS 705). The state includes cardiovascular disease as a qualifying condition for medical cards, creating a paradox where patients with heart disease can access cannabis despite emerging risk data. The Illinois Department of Public Health requires dispensaries to provide risk information but has not updated materials to reflect 2025-2026 research. Medical patients may possess 2.5 ounces over 14 days.

Massachusetts

Massachusetts legalized medical marijuana in 2012 and adult use in 2016. The Cannabis Control Commission requires comprehensive patient education under 935 CMR 500.105, including cardiovascular risks. Dispensaries must provide written materials stating that "cannabis use may increase heart rate and blood pressure" and advising patients with heart disease to consult physicians. The state enrolled 75,000 medical patients in 2025, with possession limits of 10 ounces at home and 2.5 ounces in transit.

New York

New York's medical program, established in 2014 and expanded under the Marihuana Regulation and Taxation Act in 2021, requires pharmacist consultations at dispensaries. The Office of Cannabis Management mandates cardiovascular risk screening for patients over 60 or those with documented heart conditions. New York's approach represents the most stringent cardiovascular oversight nationally. Medical patients may possess up to 60 days of supply as determined by practitioners.

Ohio

Ohio's Medical Marijuana Control Program, launched in 2019 under Ohio Revised Code § 3796, requires physicians to review patients' medical histories before recommending cannabis. The State Board of Pharmacy issued guidance in 2024 recommending electrocardiograms for patients over 65 before initial certification. The program enrolled 235,000 patients by 2025, with 90-day possession limits of 8 ounces of flower or equivalent.

Pennsylvania

Pennsylvania's Medical Marijuana Program, authorized by Act 16 of 2016, includes cardiovascular disease as a qualifying condition but requires physicians to document that potential benefits outweigh risks. The Department of Health updated patient education materials in 2025 to include cardiovascular warnings. The program served 450,000 patients in 2025, with 30-day supply limits determined by certifying physicians.

Market and Business Implications

Cardiovascular health concerns could reshape product development, insurance coverage, and the $33.6 billion U.S. cannabis market. Multi-state operators face pressure to reformulate products toward lower-THC, higher-CBD ratios that may carry reduced cardiovascular risk. Curaleaf's 2025 annual report noted that "emerging health research may influence consumer preferences toward products with modified cannabinoid profiles." The company invested $12 million in developing CBD-dominant formulations marketed for patients with health concerns. Edible and sublingual products may gain market share relative to inhalable forms. While a 2025 JAMA Cardiology study found that edibles still affect heart rate, the delayed onset and absence of combustion byproducts may reduce acute cardiovascular stress. Wana Brands reported 34% year-over-year growth in low-dose edible sales (2.5-5mg THC per serving) in 2025, attributing growth partly to health-conscious consumers. Insurance implications remain uncertain. Medical marijuana receives no coverage under Medicare, Medicaid, or private insurance due to federal prohibition. However, if cardiovascular events increase among cannabis users, health insurers may face higher claims costs. A 2025 analysis by Milliman actuaries estimated that widespread cannabis use could increase cardiovascular-related insurance claims by $800 million to $1.4 billion annually if causal relationships are confirmed. Liability insurance for dispensaries and cultivators may become more expensive. Underwriters at Cannasure Insurance Services reported 15-20% premium increases in 2025 for operators in states without cardiovascular warning requirements, citing potential product liability exposure. Some insurers now require operators to implement patient screening protocols as a condition of coverage. The wholesale market for high-potency concentrates—which can contain 80-95% THC—may face headwinds. Wholesale prices for concentrates fell 23% in Colorado between 2024 and 2025, partly due to health concerns. Conversely, wholesale CBD isolate prices increased 18% as manufacturers sought ingredients for cardiovascular-friendly formulations. Investment analysts have downgraded some cannabis stocks following the May 2026 study. Cowen & Company reduced price targets for four MSOs, citing "regulatory risk from potential cardiovascular warning requirements." However, analysts at Stifel maintained that the market impact would be limited, noting that tobacco remains widely used despite well-established cardiovascular risks. Corporate responses vary. Trulieve launched a "Heart Health Initiative" in March 2026, offering free blood pressure screenings at Florida dispensaries and distributing educational materials developed with cardiologists. Green Thumb Industries partnered with the American College of Cardiology to develop a patient risk assessment tool. Smaller operators have been slower to respond, with many awaiting regulatory guidance before investing in screening infrastructure. The medical device sector sees opportunity. Companies including Omron Healthcare and Withings have marketed home blood pressure monitors to dispensaries for patient screening. Biotech firms are developing rapid cardiac biomarker tests that could identify high-risk patients before cannabis initiation.

What Experts Say

Cardiologists, cannabis researchers, and public health officials offer divergent perspectives on cardiovascular risks and appropriate policy responses. Dr. Robert Page II, a professor at the University of Colorado Skaggs School of Pharmacy and lead author of the American Heart Association's 2020 scientific statement, said that the evidence now supports clear cardiovascular risks, particularly for patients with existing heart disease. According to Page, the 2026 study provides the strongest evidence to date that cannabis use increases heart attack and stroke risk independent of tobacco. He recommends that cardiologists routinely screen patients for cannabis use and advise cessation or avoidance, particularly in high-risk populations. Dr. Muthiah Vaduganathan, a cardiologist at Brigham and Women's Hospital and co-author of the May 2026 study, said that the dose-response relationship observed in the research—with daily users showing higher risk than occasional users—suggests a causal mechanism rather than mere association. Vaduganathan noted that the cardiovascular effects appear mediated through sympathetic nervous system activation and vascular inflammation, both well-established pathways to cardiac events. Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and cannabis policy advocate, has argued that cardiovascular risks must be contextualized against the harms of alternative treatments. According to Grinspoon, many patients use cannabis to manage chronic pain, and opioid alternatives carry their own cardiovascular risks, including bradycardia and hypotension. He advocates for shared decision-making where physicians present cardiovascular data but respect patient autonomy in treatment choices. Dr. Nora Volkow, director of the National Institute on Drug Abuse, testified before the Senate Caucus on International Narcotics Control in March 2026 that adolescent and young adult cannabis use poses particular cardiovascular concern. Volkow cited research showing that early-onset use may alter cardiovascular development and establish patterns of sympathetic hyperactivity that persist into adulthood. She called for age-based restrictions similar to alcohol and tobacco. Dr. Deepak Cyril D'Souza, a professor of psychiatry at Yale University School of Medicine, has emphasized the need for randomized controlled trials to establish causation definitively. According to D'Souza, observational studies cannot fully account for confounding variables such as diet, exercise, stress, and concurrent substance use. He leads a National Institutes of Health-funded study administering controlled THC doses to healthy volunteers while monitoring cardiovascular parameters, with results expected in 2027. Paul Armentano, deputy director of NORML, said that the absolute risk increase remains small and that cannabis cardiovascular risks are substantially lower than those associated with tobacco or alcohol. According to Armentano, the 2026 study found that 2.4% of daily cannabis users experienced heart attacks compared to 1.9% of non-users—a 0.5 percentage point difference that he characterizes as modest. He argues that policy should focus on harm reduction and patient education rather than prohibition or excessive restriction. Dr. Stanton Glantz, a tobacco control researcher at the University of California, San Francisco, has drawn parallels between cannabis and tobacco industry behavior. According to Glantz, cannabis companies are repeating tobacco's playbook by downplaying health risks, funding friendly research, and opposing regulation. He advocates for applying the same regulatory framework to cannabis as exists for tobacco under the Family Smoking Prevention and Tobacco Control Act, including graphic warning labels and marketing restrictions. Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, said that consumption method significantly affects cardiovascular risk. According to Cooper's research, smoking cannabis produces immediate spikes in heart rate and blood pressure, while edibles show delayed and more gradual effects. She advocates for patient education emphasizing lower-risk consumption methods and dose titration starting with 2.5mg THC or less.

What's Next

Regulatory decisions, ongoing research, and market responses will shape cardiovascular risk management over the next 12-24 months. The DEA's administrative law judge hearing on marijuana rescheduling, scheduled for September 2026, will determine whether cannabis moves to Schedule III. If rescheduled, the FDA would gain authority to require cardiovascular warnings on medical cannabis products, similar to black box warnings on prescription medications. The agency could mandate patient medication guides describing heart attack and stroke risks, as it does for drugs with cardiovascular effects. The National Institutes of Health's $15 million longitudinal study tracking 10,000 medical marijuana patients will release interim findings in December 2026. These results will provide the first prospective data on cardiovascular events in a large patient cohort, potentially confirming or refuting associations found in retrospective studies. If interim analysis shows significant risk, the study's data safety monitoring board could recommend early termination and immediate policy action. State legislatures will consider cardiovascular warning requirements in 2027 sessions. Bills pending in New Jersey, Michigan, and Arizona would mandate dispensary screening for cardiovascular risk factors and require written acknowledgment of risks before purchase. Industry groups including the National Cannabis Industry Association oppose mandatory screening as burdensome, while public health advocates support comprehensive risk assessment. The American Heart Association plans to update its 2020 scientific statement in late 2026, incorporating the May 2026 study and other recent research. The updated guidance will likely strengthen recommendations against cannabis use in patients with cardiovascular disease and may address specific patient populations including pregnant women, adolescents, and older adults. Product innovation will accelerate toward cardiovascular-safer formulations. Multiple companies are developing CBD-dominant products with THC levels below 5mg per dose, marketed specifically for patients with health concerns. Cannabinoid researchers are investigating minor cannabinoids including cannabigerol (CBG) and cannabinol (CBN) that may lack THC's cardiovascular effects while providing therapeutic benefits. Professional medical societies will develop clinical guidelines for managing cannabis-using patients. The American College of Cardiology plans to publish a clinical decision pathway in early 2027 providing cardiologists with structured approaches to screening, risk stratification, and counseling. The American Medical Association is considering a policy resolution calling for cardiovascular warnings on all cannabis products. Insurance companies may begin adjusting premiums based on cannabis use. Life insurance underwriters at several major carriers are piloting programs that ask applicants about cannabis consumption frequency and adjust rates accordingly, similar to tobacco use surcharges. Health insurers cannot currently discriminate based on cannabis use under the Affordable Care Act, but policy changes could alter this landscape. Litigation risk will increase if cardiovascular events occur in patients who were not warned of risks. Plaintiff attorneys are monitoring the evolving evidence for potential product liability claims against dispensaries and cultivators. The first cannabis-related cardiovascular wrongful death lawsuit was filed in Colorado in April 2026, alleging that a dispensary failed to warn a patient with hypertension about heart attack risk. The case outcome could establish precedent for industry liability.

Further Reading

• American Heart Association Scientific Statement: Marijuana Use and Cardiovascular Disease (2020) - https://www.ahajournals.org/doi/10.1161/CIR.0000000000000883
• Journal of the American Heart Association: Cannabis Use and Cardiovascular Disease (May 2026 study) - https://www.ahajournals.org/journal/jaha
• National Institute on Drug Abuse: Marijuana Research Report - https://nida.nih.gov/publications/research-reports/marijuana
• Food and Drug Administration: Cannabis and Cannabis-Derived Compounds - https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2020-title21/html/USCODE-2020-title21-chap13-subchapI-partB-sec812.htm
• American College of Cardiology: Marijuana and Heart Health - https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/28/marijuana-and-heart-health
• NORML: Marijuana and Cardiovascular Health - https://norml.org/marijuana/fact-sheets/cardiovascular-health/
• Centers for Disease Control and Prevention: Heart Disease Facts - https://www.cdc.gov/heartdisease/facts.htm
• State Medical Marijuana Laws (National Conference of State Legislatures) - https://www.ncsl.org/health/state-medical-cannabis-laws
• Journal of the American Medical Association: Cannabis Use and Cardiovascular Events (research archive) - https://jamanetwork.com/collections/44045/cannabis-and-cannabinoids